The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), released updated treatment recommendations for patients with psoriatic arthritis (PsA). In the recommendations, they list specific treatment options for patients with PsA and key comorbidities associated with the disease, including screening patients for mood disorders such as depression and anxiety.
In your practice, how often do you screen your patients with PsA for mood disorders such as depression and/or anxiety?